Kathryn Pickard Barrister 11 South Square

Slides:



Advertisements
Similar presentations
LEGAL 101 – Two Favourite Concepts: 1.Without Prejudice and 2.Client Legal Privilege THINK.CHANGE.DO.
Advertisements

Competence and Capacity
From POM to P From POM to P Wellard’s NHS training wellards.co.uk 2004.
Autonomy and Beneficence.  Right to make one’s own choices  Respect for persons- not to interfere with choice of another, though persuasion permitted.
What You Need to Know About Biosimilars: Products, Recent Deals, IP Issues and Licensing August 2, 2012 Madison C. Jellins 1.
Informed Consent in Mental Health. Context Relevant Legislation The Process of Informed Consent.
Enforcement in the Pharmaceutical Industry Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s Office District of Massachusetts October.
Obtaining Informed Consent: 1. Elements Of Informed Consent 2. Essential Information For Prospective Participants 3. Obligation for investigators.
The European Union legal framework for clinical data access: The European Union legal framework for clinical data access: potential challenges and opportunities.
Mr. Beerbower McHenry High School
A New Pathway for Follow-on Biologics Presented by: Steve Nash May 7, 2010.
CHAPTER 19 WARRANTIES AND PRODUCT LIABILITY DAVIDSON, KNOWLES & FORSYTHE Business Law: Cases and Principles in the Legal Environment (8 th Ed.)
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA AN OVERVIEW OF PATENT PROTECTION IN ZAMBIA.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
SAREE AONGSOMWANG Foundation for Consumers, Thailand.
11 Indirect Infringement of Patent for Combination of Drugs Kaoru Kuroda, Attorney at Law Abe, Ikubo & Katayama ABE, IKUBO & KATAYAMA.
Data protection and extension of patent rights TRIPS requirements & TRIPS-plus provisions Carlos Correa.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Understanding Medicines Ch. 23 pp Lesson 1: The Role of Medicines Classification of Medicines A.Prevent disease B.Fight pathogens C.Relieve.
When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.
U.S. Copyright Enforcement Benjamin Hardman Attorney / Advisor Office of Intellectual Property Policy & Enforcement, USPTO.
Anthony C. Tridico, Ph.D. AIPLA BIOTECHNOLOGY COMMITTEE Pinning Down a Moving Target: Patenting Biotech in Uncertain Times.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
Page 1 Implementation of the WTO Decision on TRIPS and Public Health Government of Canada August 2004.
Infringement Claims and Defenses Professor Todd Bruno.
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
ADAMS & ADAMS Intellectual Property within the Pharmaceutical Industry Presentation to SAPRAA. 04 September 2009 By : Alexis Apostolidis B.Sc (Chem, Law);
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
 the study of the rightness or wrongness of human conduct.  In any situation involving two or more individuals, values may come into conflict and ethical.
FGM – THE ENHANCED DATASET DR EMMA TUKMACHI LEAD GP FOR SAFEGUARDING CHILDREN IN TOWER HAMLETS.
The Research Use Exception to Patent Infringement Earlier cases Whittemore v. Cutter 29 F. Cas (C.C.D. Mass. 1813) “It could never have been the.
CONDITIONSANDWARRANTIES. STIPULATION STIPULATION A stipulation in a contract of sale with reference to goods which are the subject thereof may be a condition.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
Consent & Vulnerable Adults Aim: To provide an opportunity for Primary Care Staff to explore issues related to consent & vulnerable adults.
Investigational Devices and Humanitarian Use Devices June 2007.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
Content and interpretation of Contracts The vast majority of the contracts pose no problems - they are usually a simple interchange of cash for goods/services.
IP and the working archive Issues arising from the use of Mass Observation Elizabeth Dunn Gaby Hardwicke - Solicitors & Trade Mark Attorneys.
0 Ethics Lecture Essentials of Informed Consent. ACADEMY OF OPHTHALMOLOGY The speaker has no financial interest in the subject matter.
Key Knowledge Confidentiality Year 4 Medical Ethics and Law Thread Course The Ethox Centre, University of Oxford.
1 Bolar Provisions in Europe Robert Watson Chartered Patent Attorney European Patent Attorney AIPLA, February 2006.
Disclaimer This presentation is intended only for use by Tulane University faculty, staff, and students. No copy or use of this presentation should occur.
BY : Dr.Roshini Murugupillai. Pharmacology (Greek : pharmacon – drug ; logos – discourse in) It is the science of drugs It deals with interaction of exogenously.
Conditions and warranties. Introduction The law relating to sale and purchase of goods, prior to 1930 were dealt by the Indian Contract Act, In.
TRADE SECRETS workshop I © 2009 Prof. Charles Gielen EU-China Workshop on the Protection of Trade Secrets Shanghai June 2009.
PHARMACEUTICAL GUIDELINES: BASIC PRINCIPLES AND STATUTES.
Brussels Privacy Symposium on Identifiability
Off-label Use.
Brussels Privacy Symposium on Identifiability
Fundamentals of business law, 10e
How to Put Together an IDE Application
Handout 2: Data Protection and Copyright
Patent law update.
Generic Medicines.
Principles of Health Care Ethics
TORTS RELATING TO INCORPOREAL PROPERTIES
R&D; Goodwill; Intangible Assets and Brands
Managing Student Records Legally and Effectively
Patient Autonomy & Informed consent
Ethics in Research.
Patents, Cannabis, and the Current U.S. Climate
R&D; Goodwill; Intangible Assets and Brands
IAPP TRUSTe SYMPOSIUM 9-11 JUNE 2004
Opening an IND: Investigator Perspective
JUSTIN TURNER QC.
Ch 18: Pharmacy.
Patent enforcement in Poland – Hot topics
2019 MEDICARE AGE-IN STUDY SENIOR MARKET INSIGHTS SERVICE Part IV
Presentation transcript:

Kathryn Pickard Barrister 11 South Square Intention, off-label prescriptions and new use patents after Warner-Lambert Kathryn Pickard Barrister 11 South Square

Second medical use claims Swiss-form claims: “Use of X for the preparation of a pharmaceutical for treating Y” EPC 2000 claims: “Product X for the treatment of Y”

Manufacturer Manufacturer Distributor Distributor Pharmacist Prescription Clinician Patient Generic skinny-label product Branded full-label product

The problem “The choice lies between defining infringement so widely that manufacturers will be dissuaded from producing generic drugs even to fulfil the original (no longer patented) use, and defining it so narrowly that patentees are inadequately protected from the invasion of their newly patented second use by generic manufacturers” Per Lord Briggs, §123

Competing policy considerations Provide reasonable protection to the second medical use patentee to reward and incentivise research Allow the public the benefit of the product for its original therapeutic use once the patent covering that original use has expired Provide reasonable legal certainty for those engaged in the manufacture, marketing and prescribing of generic drug for the non-patented use that their conduct is lawful Protect the autonomy of clinical judgments

Legal Context A person infringes a patent for an invention if, without the consent of the proprietor, he: where the invention is a product, makes, disposes of, offers to dispose of, uses, or imports the product or keeps it for those purposes (s.60(1)(a)) where the invention is a process, disposes of, offers to dispose of, uses or imports any product obtained directly by means of that process or keeps any such product whether for disposal or otherwise (s.60(1)(c))

Statutory provision = strict liability Product claims – s.60(1)(a) - makes - disposes of -offers to dispose of - uses - imports - keeps Process claims – s.60(1)(c) - disposes of - offers to dispose of - uses - imports - keeps Claim construction = possibility of mental element EPC 2000 claim “Product X for the treatment of Y” Swiss-form claim “Use of X for the preparation of a pharmaceutical for treating Y”

What does ‘for’ mean? “intended for” i.e. subjective intention “where it is known or reasonably foreseeable that some of the medicine will be used for” i.e. reasonable foreseeability “…some of the medicine will be intentionally used for” “…where the manufacturer has not taken all reasonable steps to prevent use for the patented treatment occurring” “where from its outward appearance it can objectively be said to be for” i.e. outward appearance – no mens rea at all

Reasonable foreseeability “The foreseeability test has the merit of being objective, but there is in my view little else to commend it” Per Lord Sumption, §79 All product infringes Flexible remedy regime? Possibility of negating if all reasonable steps taken to prevent use for patented indication?

Subjective intention “It seems unsatisfactory that patent infringement should depend on investigation of a subjective intention, internal to the manufacturer” Per Lord Mance, §204 Is manufacturer targeting the market for patented or non-patented use? Reflects purpose of Swiss-form claim Balances rights of patentee against those of generic manufacturer Commercial certainty for third parties? Evidential problems?

Outward appearance “…the intention of the manufacturer…is irrelevant to the question of infringement…in a purpose-limited process claim, the badge of purpose is the physical characteristics of the product as it emerges from the relevant process” Per Lord Sumption, §§83-84 Objective test Commercial certainty to manufacturer and third parties dealing in product Sufficient protection for patentee? Charade?

Further issues How should outward appearance test be applied? What, if anything, must manufacturer do to make clear that permitted use is limited? In what, if any, circumstances is it legitimate to look at factors external to the product? What should the test for EPC 2000 claims be?